(redirected from Mozobil)


(ple-rix-a-fore) ,


(trade name)


Therapeutic: none assigned
Pharmacologic: hematopoietic stem cell mobilizers
Pregnancy Category: D


Mobilizes hematopoietic stem cells to peripheral blood for collection and use in autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma; used in combination with granulocyte-colony stimulation factor (G-CSF).


Inhibits the CXCR-4 chemokine receptor, blocking it's binding ability. Inhibition decreases adherence of stem cells to bone marrow, freeing them up to mobilize to peripheral blood.

Therapeutic effects

Mobilization of stem cells to peripheral blood allowing collection.


Absorption: Well absorbed following subcut administration.
Distribution: Largely confined to extravascular fluid space.
Metabolism and Excretion: Not metabolized by the liver; 70% unchanged in urine.
Half-life: 5.3 hr.

Time/action profile (mobilization of cells)

Subcutrapid10–14 hr*unknown
*With G-CSF pretreatment.


Contraindicated in: Hypersensitivity;Leukemia; Obstetric / Lactation: Pregnancy or lactation.
Use Cautiously in: Renal impairment (dose ↓ required if CCr ≤50 mL/min); Geriatric: Consider age-related ↓ in renal function and greater sensitivity to drug effects; Obstetric: Women with child-bearing potential; Pediatric: Safety and effectiveness not established.

Adverse Reactions/Side Effects

Central nervous system

  • dizziness (most frequent)
  • fatigue (most frequent)
  • headache (most frequent)
  • insomnia


  • splenic rupture (life-threatening)
  • diarrhea (most frequent)
  • nausea (most frequent)
  • vomiting (most frequent)
  • abdominal distention/pain
  • constipation
  • dry mouth
  • dyspepsia
  • flatulence


  • erythema
  • sweating


  • leukemia/tumor cell mobilization
  • thrombocytopenia


  • injection site reactions (most frequent)


  • musculoskeletal pain


  • oral hypoesthesia


  • anaphylaxis (life-threatening)


Drug-Drug interaction

None noted.


Subcutaneous (Adults) Following pretreatment with G-CSF for 4 days—0.24 mg/kg once daily for up to 4 days (not to exceed 40 mg/day); use actual body weight to calculate dose.

Renal Impairment

Subcutaneous (Adults) Following pretreatment with G-CSF for 4 days—0.16 mg/kg once daily for up to 4 days (not to exceed 27 mg/day).


Solution for subcutaneous injection: 20 mg/mL

Nursing implications

Nursing assessment

  • Assess for splenic enlargement and potential rupture (left upper abdominal pain and/or scapular or shoulder pain) periodically during therapy.
  • Monitor for signs and symptoms of anaphylaxis (urticaria, periorbital swelling, dyspnea, hypoxia) during and for at least 30 min following administration. Discontinue therapy and treat symptomatically if symptoms occur.
  • Lab Test Considerations: Monitor WBC and platelets during therapy. May cause leukocytosis and thrombocytopenia.

Potential Nursing Diagnoses

Deficient knowledge, related to medication regimen (Patient/Family Teaching)


  • Begin therapy after patient has received 4 days of G-CSF daily and approximately 11 hrs prior to initiation of apheresis.
  • Subcutaneous: Administer subcut daily for 4 days. Do not use solutions that are discolored or contain a precipitate. Vials are single use; discard any unused medication.

Patient/Family Teaching

  • Explain purpose of medication to patient.
  • Advise patient to report signs and symptoms of potential systemic reactions (urticaria, periorbital swelling, dyspnea, hypoxia) to health care professional.
  • Instruct patient to notify health care professional immediately if vasovagal reactions (orthostatic hypotension, syncope) occur during or shortly after injection.
  • Advise patient to notify health care professional if itching, rash, or reactions at injection site occur; may be treated with OTC medications.
  • May cause GI disorders including diarrhea, nausea, vomiting, flatulence, and abdominal pain. Advise patient to notify health care professional if GI disorders are severe.
  • Plerixafor is teratogenic. Caution female patients to use effective contraception during therapy and to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Increase in CD34+ cells/kg in peripheral blood prior to aphresis.
References in periodicals archive ?
Previously, the investigators treated another three WHIM syndrome patients with plerixafor (Mozobil), which was well tolerated and led to sustained increases in circulating neutrophils, lymphocytes, and monocytes.
Finally, there are data describing the superior effects of some new agents in combination with G-CSF, such as plerixafor or mozobil (antagonist of the alpha chemokine receptor CXCR4) in mobilizing the CD[34.sup.+] cells - including the immature SCs, capable for durable or late (long-term) BM repopulation with following hematopoietic reconstitution [2, 14].
The company says solid performances from Jevtana and Mozobil were offset by the impact of generic versions of Taxotere in Japan.
In the modern method, stem cells are mobilized from the bone marrow using granulocyte colony-stimulating factor (G-CSF), often with the addition of a mobilizing agent such as Plerixafor (Mozobil), harvested from the donor's peripheral blood by apheresis, and infused to the patient after chemotherapy ablation treatment.
The Western Mail earlier this year featured the Thomases' ultimately successful fight to receive the drug mozobil, which would help the 49-year-old to produce sufficient stem cells for a transplant to keep the disease in remission.
The Genzyme Corporation, Cambridge, MA, announced the European Commission (EU) has granted it marketing authorization for Mozobil (plenixafor injection), as a treatment option for patients with the blood cancers lymphoma and multiple myeloma who require an autologous stem cell transplant.
They treated healthy mice with one of two different 'growth factors' - proteins that occur naturally in the bone marrow - called VEGF and G-CSF, after which, the mice were given a new drug called Mozobil.
said its experimental treatment for blood cancer, Mozobil, was effective in a study at elevating the level of stem cells in the blood of patients with lymphoma.
Genzyme proposed revising its tender offer following the completion of additional diligence regarding Mozobil, AnorMED's lead product candidate, and the other assets owned by AnorMED.
An open label, pilot study of CDX-301, alone and in combination with Mozobil (plerixafor), in sibling-matched donors for allogeneic hematopoietic stem cell transplantation (HSCT) recipients who have certain hematologic malignancies is enrolling donor/patient pairs.
An open label, pilot study of CDX-301, alone and in combination with Mozobil (plerixafor), in siblingmatched donors for allogeneic hematopoietic stem cell transplantation (HSCT) recipients who have certain hematologic malignancies is enrolling donor/patient pairs.
Myeloma UK has said fewer patients are being prescribed the drug Mozobil since it was approved for use in Wales than before the All Wales Medicines Strategy Group (AWMSG) said yes in March.